entertainment -WSS

entertainment

author：leisure time 2025-10-01 00:58:55 - browse：58

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： It costs an awful lot of money to give away a kidney

focus

WSS

Pregnancy ages women, but effects reverse after delivery

CDC recommends RSV monoclonal antibody for infants

Testing GLP

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

U.K. officials, researchers try to ease path for bespoke genetic treatments

Biotech investment managers search for lucrative opportunities

hotspot

entertainment

Wikipedia

Medicare details structure of new drug price negotiation program

Cancer, immunology, HIV research ensnared in fetal tissue politics

The cancer drug shortage isn’t new — and neither are the solutions

H.R. 3 is the wrong path to lower drug costs

Apple is now the first public company to be valued at $3 trillion

Cancer, immunology, HIV research ensnared in fetal tissue politics

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Heart disease in astronauts blamed on cosmic radiation

Activists slam private health insurers over coverage restrictions

6 surprising facts about sugar

Wikipedia

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Asbestos ban is immediate, but health effects will linger for decades

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Alnylam reports growth in sales of rare disease treatments

Cancer, immunology, HIV research ensnared in fetal tissue politics

Pregnancy ages women, but effects reverse after delivery

leisure time

entertainment

focus

focus